New developments in A1 and A2 adenosine receptor antagonists*
K. Kiec´-Kononowicz1,#, A. Drabczyn´ska1, E. Pekala1, B. Michalak1,
C. E. Müller2, B. Schumacher2, J. Karolak-Wojciechowska3, H. Duddeck4,
S. Rockitt4, and R. Wartchow4
1Jagiellonian University, Medical College, Department
of Chemical Technology of Drugs, Medyczna 9, Pl 30-688 Kraków,
Poland; 2Pharmaceutical Institute Poppelsdorf, University of Bonn, Kreuzbergweg
26, D-53115 Bonn, Germany; 3Institute of General and Ecological Chemistry,
Technical University of L/ódz´, Z·wirki 36, Pl 30-924
L/ódz´, Poland; 4University of Hannover, Institute of Organic
Chemistry, Schneiderberg 1B, D-30167 Hannover, Germany
Abstract: The aim of this article is to briefly present progress
in the development of the potent adenosine receptor (AR) antagonists
with high selectivity for either A1, A2A, or A2B ARs. The structural
requirements for each AR subtype were discussed as well as their potential
therapeutic use. In the search for new AR antagonists, series of imidazo-,
pyrimido-, and diazepino-purindione derivatives as well as oxazolo-,
oxazino-, and oxazepino-purindiones were designed, synthesized, and
preliminarily evaluated in pharmacological studies. Oxygen-containing
tricyclic derivatives were shown to be moderately potent AR antagonists
exhibiting selectivity either for A1 or A2A ARs. Tricyclic purindiones
with nitrogen in the third ring were generally more A2A AR selective.
The compounds tested in vivo according to the Antiepileptic Drug Development
Program of the National Institutes of Health (USA) were generally active
as anticonvulsants in chemically induced seizures.
*Plenary lecture presented at the Hungarian-German-Italian-Polish
Joint Meeting on Medicinal Chemistry, Budapest, Hungary, 2 –6 September
2001. Other presentations are published in this issue, pp.
1387-1509.
# Corresponding author.
Back to Contents for access to full
text
